Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-cash Items (2017 - 2025)

Dianthus Therapeutics has reported Non-cash Items over the past 6 years, most recently at $126.2 million for Q3 2025.

  • Quarterly results put Non-cash Items at $126.2 million for Q3 2025, up 9983.95% from a year ago — trailing twelve months through Sep 2025 was $126.2 million (up 9983.95% YoY), and the annual figure for FY2024 was $24.9 million, up 681.74%.
  • Non-cash Items for Q3 2025 was $126.2 million at Dianthus Therapeutics, up from $2.2 million in the prior quarter.
  • Over the last five years, Non-cash Items for DNTH hit a ceiling of $126.2 million in Q3 2025 and a floor of $776110.0 in Q1 2024.
  • Median Non-cash Items over the past 4 years was $2.7 million (2023), compared with a mean of $18.3 million.
  • Biggest five-year swings in Non-cash Items: crashed 83.88% in 2024 and later soared 9983.95% in 2025.
  • Dianthus Therapeutics' Non-cash Items stood at $1.7 million in 2022, then surged by 87.12% to $3.2 million in 2023, then soared by 681.74% to $24.9 million in 2024, then surged by 407.6% to $126.2 million in 2025.
  • The last three reported values for Non-cash Items were $126.2 million (Q3 2025), $2.2 million (Q2 2025), and $14.0 million (Q1 2025) per Business Quant data.